On December 31, 2021, Charles H. Randall, chief strategy officer of SAB Biotherapeutics, Inc. resigned. The company and Mr. Randall are finalizing the terms of a release and severance under his employment agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.69 USD | +0.75% | -1.10% | -60.87% |
30/05 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
21/05 | FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.87% | 24.63M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- SAB Biotherapeutics, Inc. Announces Resignation of Charles H. Randall as Chief Strategy Officer